Avidity Partners Management has significantly increased its stake in Oruka Therapeutics, acquiring 100,000 shares valued at approximately $3.48 million, as disclosed in a May 13, 2026 SEC filing. This purchase raises Avidity’s total investment in Oruka to $52.02 million, representing 11.77% of its reportable assets and reflecting strong confidence in the biotech firm’s growth potential.
Oruka Therapeutics has seen its stock soar 563.1% over the past year, vastly outperforming the S&P 500’s 26% increase. The company’s promising pipeline, particularly the Phase 2a results for ORKA-001 in psoriasis, has fueled investor enthusiasm. The treatment demonstrated a 63.5% complete skin clearance rate at Week 16, and management’s focus on once-yearly dosing could provide a competitive edge in the market.
For market professionals, Avidity’s decision to bolster its position amid a substantial rally signals robust conviction in Oruka’s long-term prospects, particularly if ORKA-001 continues to demonstrate superior efficacy and safety in future trials.
Source: fool.com